Sarah Schaefer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sarah Schaefer has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Emily Walits
Department of Infection Prevention, The Mount Sinai Hospital , New York, New York , USA
2 shared publicationsGopi Patel
Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai , New York, New York , USA
2 shared publications- Adam Pobliner
Crothall Healthcare, Wayne, PA
1 shared publication - Adolfo Firpo-Betancourt
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication - Alberto Enrique Paniz-Mondolfi
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
1 shared publication - Bernadette Liggayu
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
1 shared publication
Latest Publications
- Open Access
- 19 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae148
Impact of the COVID-19 Pandemic on Candida auris Infections: A Retrospective Analysis in an Academic Medical Center in New York City
Candida auris, a multidrug-resistant fungus first described in Japan in 2009, has since then spread rapidly around the world. More recently, cases of C. auris have increased substantially, which may have been affected by the strain the COVID-19 pandemic placed on healthcare resources. We describe the epidemiology of C. auris infection and colonization at a tertiary care hospital in New York City before, during, and after the peak of the COVID-19 pandemic and describe our approach to surveillance. We performed a retrospective chart review for all incident cases of C. auris, defined as a patient without a known history of infection or colonization, who had a positive surveillance or clinical culture detected at our institution from 2019 through 2022. Clinical and demographic data were collected using the electronic medical record. Sixty-four incident cases of C. auris were identified. Thirty-four of these were identified by surveillance and 30 by clinical culture. There was a statistically significant increase in the number of cases identified in 2022 compared with 2019, with incidence rates of 2.6 cases per 10,000 admissions in 2019 and 7.8 cases per 10,000 admissions in 2022 (p = 0.002), respectively. The incidence of C. auris colonization or infection increased significantly at our institution during the COVID-19 pandemic suggesting the potential impact the pandemic had on C. auris transmission. Targeted admission surveillance allows for the early identification of C. auris cases and can serve as a valuable tool to combat the increasing transmission of C. auris.
- 19 March 2024
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 11 (6) , ofae148
Open AccessImpact of the COVID-19 Pandemic on Candida auris Infections: A Retrospective Analysis in an Academic Medical Center in New York City
Candida auris, a multidrug-resistant fungus first described in Japan in 2009, has since then spread rapidly around the world. More recently, cases of C. auris have increased substantially, which may have been affected by the strain the COVID-19 pandemic placed on healthcare resources. We describe the epidemiology of C. auris infection and colonization at a tertiary care hospital in New York City before, during, and after the peak of the COVID-19 pandemic and describe our approach to surveillance. We performed a retrospective chart review for all incident cases of C. auris, defined as a patient without a known history of infection or colonization, who had a positive surveillance or clinical culture detected at our institution from 2019 through 2022. Clinical and demographic data were collected using the electronic medical record. Sixty-four incident cases of C. auris were identified. Thirty-four of these were identified by surveillance and 30 by clinical culture. There was a statistically significant increase in the number of cases identified in 2022 compared with 2019, with incidence rates of 2.6 cases per 10,000 admissions in 2019 and 7.8 cases per 10,000 admissions in 2022 (p = 0.002), respectively. The incidence of C. auris colonization or infection increased significantly at our institution during the COVID-19 pandemic suggesting the potential impact the pandemic had on C. auris transmission. Targeted admission surveillance allows for the early identification of C. auris cases and can serve as a valuable tool to combat the increasing transmission of C. auris.
- 12 October 2023
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (4) , 491-492
Outcome of Candida auris contact investigations conducted in a 6 month period at a New York City hospital
- 12 October 2023
- Published by Elsevier in American Journal of Infection Control
- Vol. 52 (4) , 491-492
Outcome of Candida auris contact investigations conducted in a 6 month period at a New York City hospital
- Open Access
- 15 August 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (8) , 849
Molecular Detection of Candida auris Using DiaSorin Molecular Simplexa® Detection Kit: A Diagnostic Performance Evaluation
Candida auris is a globally emerging fungal pathogen that is associated with healthcare-related infections. The accurate and rapid detection of C. auris is crucial for effective infection prevention, control, and patient management. This study aimed to validate the analytical and diagnostic performance of the DiaSorin Molecular C. auris Detection Kit. The analytical specificity, sensitivity, and reproducibility of the assay were evaluated. The limit of detection (LOD) was determined to be 266 CFU/µL using the ZeptoMetrix Candida auris Z485 strain and standard calibration curves. The assay demonstrated high analytical specificity and showed no amplification against a diverse panel of bacteria and fungi. Clinical validation was conducted using deidentified residual axillary/groin surveillance culture specimens from C. auris culture-positive and culture-negative patients. The DiaSorin Molecular Detection Kit exhibited 100% agreement in sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) when compared to cultures coupled with MALDI-TOF identification. Intra- and inter-reproducibility testing demonstrated consistent and reliable diagnostic performance. This validated assay offers rapid and accurate detection of C. auris, facilitating timely implementation of infection control measures and appropriate patient care. The DiaSorin Molecular C. auris Detection Kit has the potential to aid in controlling the outbreaks caused by this emerging fungal pathogen. Providing a reliable diagnostic tool can contribute to the effective management and containment of C. auris infections in healthcare settings and ultimately improve patient outcomes.
- 15 August 2023
- Published by MDPI AG in Journal of Fungi
- Vol. 9 (8) , 849
Open AccessMolecular Detection of Candida auris Using DiaSorin Molecular Simplexa® Detection Kit: A Diagnostic Performance Evaluation
Candida auris is a globally emerging fungal pathogen that is associated with healthcare-related infections. The accurate and rapid detection of C. auris is crucial for effective infection prevention, control, and patient management. This study aimed to validate the analytical and diagnostic performance of the DiaSorin Molecular C. auris Detection Kit. The analytical specificity, sensitivity, and reproducibility of the assay were evaluated. The limit of detection (LOD) was determined to be 266 CFU/µL using the ZeptoMetrix Candida auris Z485 strain and standard calibration curves. The assay demonstrated high analytical specificity and showed no amplification against a diverse panel of bacteria and fungi. Clinical validation was conducted using deidentified residual axillary/groin surveillance culture specimens from C. auris culture-positive and culture-negative patients. The DiaSorin Molecular Detection Kit exhibited 100% agreement in sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) when compared to cultures coupled with MALDI-TOF identification. Intra- and inter-reproducibility testing demonstrated consistent and reliable diagnostic performance. This validated assay offers rapid and accurate detection of C. auris, facilitating timely implementation of infection control measures and appropriate patient care. The DiaSorin Molecular C. auris Detection Kit has the potential to aid in controlling the outbreaks caused by this emerging fungal pathogen. Providing a reliable diagnostic tool can contribute to the effective management and containment of C. auris infections in healthcare settings and ultimately improve patient outcomes.
- 1 February 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (2) , 222-223
Management of Candida auris in an inpatient acute rehabilitation setting
- 1 February 2020
- Published by Elsevier in American Journal of Infection Control
- Vol. 48 (2) , 222-223
Management of Candida auris in an inpatient acute rehabilitation setting